| Ytd | 2.34% | |
| 1y | 0.00% |
| Open | 9.40 | Prev Close | 9.27 | Low | 9.00 | High | 9.40 | Mkt Cap | 60.29M |
| Vol | 11.52K | Avg Vol | 49.58K | EPS | -1.62 | P/E | -5.66 | Forward P/E | -1.91 |
| Beta | -0.20 | Short Ratio | 0.42 | Inst. Own | 29.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.72 | 200-d Avg | 8.92 | 1yr Est | 4.50 |
XLO News
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Co
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 fo
WALTHAM, Mass. , May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost ou
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinica
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by
Aligos Therapeutics (NASDAQ: ALGS - Get Free Report) and Xilio Therapeutics (NASDAQ: XLO - Get Free